New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
08:37 EDTELGXEndologix investors should add to positions, says Canaccord
Canaccord recommends investors add to positions in Endologix following investor meetings with management. The firm believes top line growth will accelerate in the second half of the year and that Nellix will make it one of the most compelling long-term growth stories in addition to making it an attractive takeover target. Shares are Buy rated with a $17.50 price target.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:16 EDTELGXEndologix trial results 'highly encouraging,' says Stifel
Subscribe for More Information
November 20, 2014
07:13 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2014
11:00 EDTELGXEndologix to host investor meeting
Subscribe for More Information
07:11 EDTELGXEndologix completes patient enrollment in Nellix EVAS FORWARD-IDE clinical trial
Endologix announced that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System for the endovascular repair of infrarenal abdominal aortic aneurysms, or AAA. Primary endpoint analysis results at one-year and beyond will be used to support the company's premarket approval, or PMA, application to the FDA for the Nellix EVAS System. The EVAS FORWARD-IDE clinical trial enrolled 179 patients at 29 centers in the U.S. and Europe. Enrollment under an extended investigation phase is anticipated to begin shortly and will continue during the pivotal trial follow-up period and PMA preparation/review process. Based on current assumptions and timelines, the company anticipates FDA approval of the Nellix System in the U.S. before the end of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use